Product Description: Mizolastine is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine effectively inhibits mRNA expression of VEGF165, VEGF120, TNF-α and KC. Mizolastine can be used in studies of allergic rhinitis and chronic idiopathic urticarial[1][2][3].
Applications: COVID-19-immunoregulation
Formula: C24H25FN6O
References: [1]Xia Q, et al. The effect of mizolastine on expression of vascular endothelial cell growth factor, tumour necrosis factor-alpha and keratinocyte-derived chemokine in murine mast cells, compared with dexamethasone and loratadine. Clin Exp Dermatol. 2005 Mar;30(2):165-70. /[2]Ren X, et al. The anti-inflammatory effects of Yunnan Baiyao are involved in regulation of the phospholipase A2/arachidonic acid metabolites pathways in acute inflammation rat model. Mol Med Rep. 2017 Oct;16(4):4045-4053./[3]Prakash A, et al. Mizolastine: a review of its use in allergic rhinitis and chronic idiopathic urticaria. BioDrugs. 1998 Jul;10(1):41-63.
CAS Number: 108612-45-9
Molecular Weight: 432.49
Compound Purity: 99.82
Research Area: Inflammation/Immunology
Solubility: DMSO : 25 mg/mL (ultrasonic)/H2O : < 0.1 mg/mL
Target: Histamine Receptor
English
Deutsch
